Compare TURB & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TURB | MYNZ |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | Spain | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 10.2M |
| IPO Year | 2023 | 2021 |
| Metric | TURB | MYNZ |
|---|---|---|
| Price | $0.68 | $0.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 46.9K | ★ 385.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.56 |
| 52 Week High | $20.44 | $5.69 |
| Indicator | TURB | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 35.62 | 25.41 |
| Support Level | $0.67 | $0.56 |
| Resistance Level | $0.74 | $1.37 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 35.61 | 7.54 |
Turbo Energy SA is a company that specializes in designing, developing, and distributing equipment for the generation, management, and storage of photovoltaic energy. The company's primary activities include acquiring, distributing, and selling electrical and electronic materials for renewable energy projects, such as solar panels, inverters, chargers, regulators, batteries, and structures. The storage products are managed through a software system optimized by artificial intelligence, which is controlled from the cloud and through the installation inverter. Turbo Energy sells inverters, batteries, and photovoltaic modules to installers and other distributors for residential consumers in Spain. Geographically it operates in Spain, Europe, and Rest of the world.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.